Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Neuhaus, Jochen ^a   Schiffer, Eric ^b   von Wilcke, Philine ^a   Bauer, Hartwig W ^c   Leung, Hing ^d   Siwy, Justyna ^b   Ulrici, Wolfram ^e   Paasch, Uwe ^a   Horn, Lars Christian ^a   Stolzenburg, Jens Uwe ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e Medical Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BIOLOGICAL MARKER; GTPASE IMAP FAMILY MEMBER 6; N ACETYLLACTOSAMINIDE BETA 1,3 N ACEYTYLGLUCOSAMINYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; SEMENOGELIN 1; SEMENOGELIN 2; STABILIN 2; TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; SEMINAL PLASMA; SENSITIVITY AND SPECIFICITY;

ADULT; AMINO ACID SEQUENCE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PEPTIDES; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SEMEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879473905     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067514     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
3. Ilic D, O'Connor D, Green S, Wilt TJ, (2011) Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 107: 882-891.
4. Siddiqui E, Mumtaz FH, Gelister J, (2004) Understanding prostate cancer. J R Soc Promot Health 124: 219-221.
5. You J, Cozzi P, Walsh B, Willcox M, Kearsley J, et al. (2010) Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 73: 10-22.
6. Goo YA, Goodlett DR, (2010) Advances in proteomic prostate cancer biomarker discovery. J Proteomics 73: 1839-1850.
7. Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, et al. (2012) Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics.
8. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, et al. (2008) Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2: 556-570.
9. Schiffer E, Bick C, Grizelj B, Pietzker S, Schofer W, (2012) Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int J Urol 19: 118-125.
10. Marshall S, (2009) Comments on the article "Biomarkers for prostate cancer" by Eric Schiffer. World J Urol 27: 577-578.
11. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, et al. (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8: 268-281.
12. Coon JJ, Shabanowitz J, Hunt DF, Syka JE, (2005) Electron transfer dissociation of peptide anions. J Am Soc Mass Spectrom 16: 880-882.
13. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF, (2004) Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci U S A 101: 9528-9533.
14. Good DM, Coon JJ, (2006) Advancing proteomics with ion/ion chemistry. BioTechniques 40: 783-789.
15. Batruch I, Lecker I, Kagedan D, Smith CR, Mullen BJ, et al. (2011) Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res 10: 941-953.
16. Kolch W, Neususs C, Pelzing M, Mischak H, (2005) Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 24: 959-977.
17. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, et al. (2009) Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 8: 335-345.
18. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, et al. (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65: 323-332.
19. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, et al. (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7: 230-240.
20. Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, et al. (2007) Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 53: 421-428.
21. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437.
22. Bright E, Manuel C, Goddard JC, Khan MA, (2010) Incidence and variables predicting Gleason score up-grading between trans-rectal ultrasound-guided prostate biopsies and radical prostatectomy. Urol Int 84: 180-184.
23. Chuang TD, Chen SJ, Lin FF, Veeramani S, Kumar S, et al. (2010) Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem 285: 23598-23606.
24. Emami N, Deperthes D, Malm J, Diamandis EP, (2008) Major role of human KLK14 in seminal clot liquefaction. J Biol Chem 283: 19561-19569.
25. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, et al. (2008) A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 7: 509-518.
26. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, et al. (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2: 46ps42.
27. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, et al. (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177: 2106-2131.
28. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
29. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, et al. (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8: 162-200.
30. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, et al. (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47: 609-615.
31. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71.
32. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, et al. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173: 1938-1942.
33. Kolch W, Neususs C, Pelzing M, Mischak H, (2005) Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 24: 959-977.
34. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, et al. (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7: 230-240.
35. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, et al. (2004) Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 18: 149-156.
36. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, et al. (2004) Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 65: 2426-2434.
37. Mischak H, Julian BA, Novak J, (2007) High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin Appl 1: 792.
38. DeLeo JM (1993) Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty. Second International Symposium on Uncertainty Modeling and Analysis 318-325.
39. Dakna M, He Z, Yu WC, Mischak H, Kolch W, (2009) Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1250-1258.
40. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological) 57: 125-133.
41. Dudoit S, van der Laan MJ (2007) Multiple testing Procedures and Applications to Genomics. Berlin: Springer Verlag. p. 1-590.
42. Girolami M, Mischak H, Krebs R, (2007) Analysis of complex, multidimensional datasets. Drug Discov Today 3: 12-19.
43. Yang ZR, (2004) Biological applications of support vector machines. Brief Bioinform 5: 328-338.
44. Yang ZR, Chou KC, (2004) Bio-support vector machines for computational proteomics. Bioinformatics 20: 735-741.
45. Metzger J, Negm AA, Plentz RR, Weismuller TJ, Wedemeyer J, et al. (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122-130.
46. Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, et al. (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27: 2111-2125.
47. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, et al. (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185: 2162-2170.
48. Cooperberg MR, Hilton JF, Carroll PR, (2011) The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117: 5039-5046.